Ten63 Therapeutics Announces Multi-Target Drug Discovery Collaboration with Boehringer Ingelheim
Ten63’s AI/ML Platform Will be Applied to Multiple Disease Areas of Focus within Boehringer’s Research and Development Portfolio
Yosemite’s Beverly Lu, Ph.D. joins Ten63’s Board of Directors
Yosemite’s Beverly Lu, Ph.D. joins Ten63’s Board of Directors
Ten63 Therapeutics Elects Steve Hall as Independent Director
Ten63 Therapeutics Elects Steve Hall as Independent Director
“Drug Hunter” and Former Venture Investor Brings Extensive Experience Launching Companies with New Drug Discovery Modalities
Oversubscribed Series A
Ten63 raises an oversubscribed $15.9M series A